Galderma, the Swiss dermatology leader, has witnessed remarkable financial growth following its 2024 IPO, with market valuation doubling in months. The company dominates the global botulinum toxin market, projected to exceed $13 billion annually. Despite facing periodic controversies, Galderma continues strengthening its position in aesthetic medicine, leveraging advanced injectables and dermatological solutions to capture expanding consumer demand for non-invasive cosmetic procedures worldwide.

Summary auto-generated by AI from the original publisher's content. Editorial standards.